FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment
CNBC
The move comes months after the Trump administration touted leucovorin as a potential therapy for a broader group of patients with autism symptoms.
The Food and Drug Administration on Tuesday approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children.
The move comes months after the Trump administration touted leucovorin as a potential therapy for a broader group of patients with autism spectrum disorder symptoms. The claim sparked skepticism among some in the medical and research community, but fueled excitement among families, spiking prescriptions of the drug in the U.S.
One FDA official told reporters Monday that "we don't have sufficient data to say that we could establish efficacy for autism more broadly" but said the agency is open to interest from companies in studying leucovorin in the autism population.
Home sales made a small gain to start the year, but higher mortgage rates now could throw cold water on the spring season.
The move comes months after the Trump administration touted leucovorin as a potential therapy for a broader group of patients with autism symptoms.
Lego on Tuesday reported a 12% jump in revenue for fiscal year 2025 and reported consumer sales that far outpace the broader toy industry.
Live Nation, which owns Ticketmaster, reached a settlement with the Department of Justice over antitrust concerns.
A growing number of consumers are seeking out third spaces and membership clubs surrounding wellness, to improve their health while also socializing.
Vinay Prasad is leaving his post as director of the Center for Biologics Evaluation and Research.
Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S. Food and Drug Administration.
A closely watched barometer for used vehicle pricing jumped last month as dealers sped to increase inventories amid optimism of a robust spring selling season.
Gap has been on a steady upswing of growth but saw worse than expected results during its holiday quarter after historic winter storms led to store closures.
Frustrated sellers who pulled homes off the market last fall are now re-listing them at a quick pace, thanks to lower mortgage rates, but supply is still low.
Travelers who are far from falling missiles, drone attacks and other geopolitical flashpoints aren't immune to ripple effects.
Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.
Target's merchandising leaders previewed the company's ambitious plans to overhaul key categories, including home and apparel, at an investor meeting.